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Guillain Barré Syndrome (GBS) in Cape Town, South Africa: a descriptive outcome cohort 
study 
Abstract 
INTRODUCTION 
Guillain-Barré syndrome (GBS) or acute inflammatory demyelinating polyradiculoneuropathy 
(AIDP) is an important cause of acute severe and life-threatening weakness. It occurs 
worldwide and may affect all age groups, but varies widely in clinical presentation, subtype, 
electrophysiology, course and outcome. There is sparse literature on GBS in low and middle 
income countries (LMIC), and the effect, if any, of HIV on GBS. This observational cohort study 
aims to describe the clinical presentation and outcome of acute GBS in Cape Town, South 
Africa, in participants recruited into the International Guillain-Barré Syndrome Outcome 
Study (IGOS). A secondary aim, given the high HIV prevalence in South Africa, is to describe 
and compare GBS participants with and without HIV infection. 
METHODS 
Between 1 June 2014 and 31 January 2017, we recruited participants 18 years or older 
presenting to Groote Schuur Hospital in Cape Town with acute GBS (< 2 weeks onset of 
symptoms) who were available for 1 year follow up. We recorded demographic, clinical, 
laboratory, electrophysiological and treatment data at entry. At follow-up at weeks 4, 26 and 
52, GBS-related complications and GBS disability scale scores (GDSs) were evaluated. A good 
outcome was defined as the ability to walk unaided (GDSs 2) by 6 months. The clinical 
presentation and outcomes of HIV-uninfected and -infected participants were compared.  
RESULTS: 
Of 31 recruited participants, 1 participant was re-diagnosed as acute onset-CIDP and excluded 
from the study and 1 participant demised of an unrelated cause within the first week. 19 
participants were male and the median age was 40 years. Reported antecedent infections 
(73%), co-morbid HIV infection (30%) and tuberculosis (15%) were frequently seen. Acute 
inflammatory demyelinating polyradiculoneuropathy (AIDP; 67%) and acute motor axonal 
neuropathy (AMAN; 17%) were the most common phenotypes.  
 Overall, GBS-related complications occurred in 46% of participants. The major complication 
was pneumonia which occurred in 23% of the total group, and all required 
intubation/ventilation. Other septic complications (drip site or systemic) were less common, 
6% of the entire group.  At entry, 83% had GDSs >4 indicating severe disability. The ability to 
walk unaided was regained by 37% at 4 weeks, 75% at 6 months and 79% at 1 year. Three 
participants remained severely affected at 1 year (GDSs of >3).  
There were no differences in antecedent infections, treatments given, or motor outcomes 
between HIV-infected and -uninfected GBS participants apart from a trend towards higher 
CSF protein in the HIV-infected group (p-value 0.05). AIDP was the most common GBS variant 
in both groups. AMAN was only seen in the HIV-uninfected group, whereas Miller Fisher 
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syndrome (MFS) was more common in the HIV-infected group. However, the numbers were 
too small to reach statistical significance. 
CONCLUSION 
Infections with HIV and tuberculosis frequently co-occurred with acute GBS, whether this 
reflects true disease association or merely high background disease prevalence cannot be 
confirmed by this study. AIDP is the most common phenotype unlike other LMIC regions such 
as Asia where AMAN predominates. In this cohort, 76% of participants showed good 
outcomes being able to walk unaided or having no/minor symptoms by 6 months. However, 
of the remainder only 1 showed significant recovery at 1 year. HIV participants had similar 
clinical presentations, complications and outcomes compared to the HIV-uninfected group. 
Mortality was low. 
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1. Introduction and literature review:
1.1  Introduction: 
Guillain-Barré syndrome (GBS) is an important cause of acute severe and life-threatening 
weakness that occurs worldwide and may affect all age groups. The diagnosis is considered in 
the presence of a combination of acute symmetrical weakness in limbs with sensory 
disturbances, and hypo- or areflexia, with a mild or absent cerebrospinal fluid cellular reaction 
despite high protein.(1) An early and accurate recognition of Guillain-Barré syndrome may be 
challenging.(2) Even though tests like lumbar puncture and electrodiagnostic studies can 
increase the level of diagnostic certainty, there are  no biological markers to reliably diagnose 
GBS. Diagnostic uncertainty therefore makes accurate determination of incidence difficult 
and estimates of incidence may vary widely. Worldwide, the incidence of GBS ranges between 
0.16 and 3.00 per 100 000 person –years (3) The clinical course and outcome of GBS patients 
varies in different geographical region. The frequency of GBS increases with age for both 
female and males. Males were more frequently affected than females in a ratio of 1.5:1. 
Worldwide, male gender and higher age are independent risk factors for developing GBS.(4) 
The incidence of GBS in South Africa is not known, and there is relatively scanty 
epidemiological data from other developing or lower and middle income countries. Whilst 
GBS is a relatively uncommon disease, it is important. It may cause substantial morbidity and 
mortality in those whom it affects, and it can be difficult to predict the outcome in individual 
patients. There is very limited literature on GBS in a South African context. It would be of 
value to describe our local experience of the clinical presentation, course and outcome of GBS 
and evaluate how this may compare with the established literature on GBS from other areas. 
The literature review that follows summarizes what is known at present about GBS 
pathogenesis, clinical presentation, HIV and GBS, complications, outcomes, treatment and 
the international cohort study; International GBS outcome study (IGOS) of which this cohort 
contributes towards. 
1.2  Antecedent infections and pathogenesis: 
GBS is postulated to be an autoimmune condition triggered by a preceding infection in up to 
half of cases.(5) It may follow infections caused by bacterial or viral pathogens most often 
affecting respiratory or gastrointestinal systems. Molecular mimicry between microbial and 
nerve antigens is said to be a major driving force behind the development of Campylobacter 
jejuni (C.jejuni) associated GBS.(6) Molecular mimicry is the sharing of homologous epitopes 
between bacterial lipopolysaccharide and ganglioside surface components of peripheral 
nerves, especially on the axolemma. It is proposed that these molecular similarities, lead to 
an antibody response against the bacteria which also attacks neuronal axons and thereby 
results in GBS in some infected individuals.(7) Campylobacter jejuni is responsible for up to 
one third of cases, but other organisms such as cytomegalovirus, Epstein-Barr virus, 
mycoplasma, Haemophilus influenzae, and influenza A virus are also detected in patients with 
GBS.(8) There is little understanding of the interaction between microbial and host factors 
that permits the immune response to shift towards autoreactivity. Furthermore, it is 
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unknown what the role is of genetic and environmental factors that may affect an individual’s 
susceptibility to develop GBS.(6) The burden of infectious diseases in the developing countries 
may influence the nature of GBS in that region. According to Islam et al (8),  who conducted 
a case control study in Bangladesh, 57 of their 100 GBS group had positive C.jejuni serology. 
The presence of this known antecedent infective trigger is hypothesized to be more frequent 
in countries with a high incidence of diarrhoea and a poor hygienic infrastructure. However, 
despite the clear link between specific infections and GBS, the chance of developing this 
severe post infectious complication is very small.(7) Tam et al (9) determined that the 
incidence of GBS among patients with Campylobacter Infection is 1.17/1000 person-years 
(95% confidence interval [CI], 0.38–3.63). The risk of GBS is believed to be elevated for only 
∼2 months after development of Campylobacter enteritis; this incidence equates to a
<2/10,000 probability that a patient with Campylobacter enteritis will develop GBS.(10) This
suggests that additional bacterial and/or host-related factors are important as well, because
not all strains expressing ganglioside mimics induce GBS.(6) Seasonality has been implicated
as a triggering factor. The seasonal variation in GBS, with high winter predominance in
Western countries, the Middle East and Far East, but summer predominance in the Indian
subcontinent and Latin America has been well established in literature. However, the
association has most frequently been weak and presumably relates to seasonal fluctuations
in infectious diseases.(11)
1.3 Clinical presentation and its variants: 
1.3.1  Diagnosis: 
The need for diagnostic criteria arose when an association was discovered between GBS and 
the swine flu vaccination campaign of 1976–1977. In 1978, the US National Institute of 
Neurological Disorders and Stroke (NINDS) developed the first case definitions for GBS. It was 
then modified by Asbury and Cornblath in 1990 and this continues to be  the most widely 
used criteria in clinical practice (see appendix A).(12) According to Asbury and Cornblath, the 
two  major features that  are required for the diagnosis of GBS; are progressive motor 
weakness and areflexia. The criteria broadly consisted of features that strongly support the 
diagnosis of GBS, and features that cast doubt and rule out the diagnosis.(13) More recently, 
the Brighton Collaboration developed a new set of case definitions for Guillain-Barré 
syndrome, in response to another possible link between Guillain-Barré syndrome and the 
H1N1 swine flu vaccination campaign of 2009/2010. The Brighton criteria identifies GBS with 
four levels of diagnostic certainty, from level 1 (highest) to level 4 (lowest). The Brighton 
criteria are not intended for clinical practice. Additional research is needed to develop criteria 
that can be used to swiftly diagnose GBS and its variants. (7) 
1.3.2 Clinical symptoms: 
GBS varies in distribution and extent of cranial nerve deficits, sensory symptoms, weakness, 
ataxia, pain, autonomic dysfunction, and the course of the disease.  Numbness and/or 
paraesthesia are the usual sensory complaints. Half of patients will have cranial nerve deficits 
in particular bilateral facial weakness, bulbar dysfunction and extraocular muscle dysfunction. 
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Pain especially painful paraesthesia, backache, myalgia and meningism occur in 54-89% of 
GBS patients.(7) Approximately a quarter of patients develop respiratory difficulties requiring 
invasive ventilation. Respiratory insufficiency develops insidiously in GBS.(14) Nadir is usually 
reached in four weeks. Studies have shown that 80% reach nadir within two weeks and 97% 
reach nadir in four weeks. Progressive phase is usually followed by a plateau phase which 
occurs from two days to six months ( median duration one week before recovery).(2)  
1.3.3 GBS and its variants: 
GBS is an extremely clinically diverse disorder and includes several clinically distinctive 
variants, formes frustes, and atypical cases. The frequency of these variants relates to the 
geographical area in which the disease is reported.(5)   
AIDP is the most common variant of GBS in Europe and North America (60-80%).(7) AIDP is a 
monophasic illness defined as an acute flaccid paralysis, characterized by symmetrical 
weakness of the limbs, and hyporeflexia or areflexia, which reaches a maximum severity 
within 4 weeks. Sensory symptoms, such as paraesthesia or numbness, usually start distally 
and have a symmetrical pattern, which is often accompanied by cranial nerve deficits and 
autonomic dysfunction (NINDS criteria for AIDP in Appendix A).(7) Electrophysiological 
studies show typical demyelination. This suggests that the immune target in this form of GBS 
is within the Schwann cell surface membrane or the myelin.(5)  
Axonal variants of GBS may also occur namely a pure motor variant, acute motor axonal 
neuropathy (AMAN), and a  sensorimotor variant, acute motor and sensory axonal 
neuropathy (AMSAN), which may be considered a severe variant of AMAN.(7) 
Electrophysiological studies confirm the motor and/or axonal degeneration. AMAN is known 
to be triggered by enteric infection, commonly C. jejuni and is frequently associated with 
antiganglioside antibodies (GM1, GM1b, GD1a or GalNAc-GD1a) AMAN occurs more 
frequently in east Asia at 60-80% (China and Japan).(15)  
The nodal and paranodal regions are important in the understanding of antiganglioside 
antibody mediated neuropathies. The axonal and demyelinating classification is ambiguous 
with regards to these neuropathies and therefore the term nodopathy is deemed more 
appropriate.(16) Nodopathies lead to disruption at the node of Ranvier with resultant 
transitory nerve conduction failure which may progress to axonal degeneration. In antiGM1 
associated AMAN, electrophysiological studies may show conduction blocks and/or slowing 
that resolve without the development of excessive temporal dispersion of action potentials. 
Owing to this rapid recovery, the patho-mechanism of injury is thought to be caused by an 
impaired physiological conduction at the node of Ranvier rather than demyelination. It may 
therefore be recognized as a nodopathy.(16) 
Miller Fisher syndrome (MFS) is another variant characterized by the triad of 
ophthalmoplegia, ataxia and areflexia and is associated with anti GQ1b antibodies.(17) Most 
of the patients with MFS present with at least two features and have supportive features like 
an elevated CSF protein and serum autoantibody. MFS represents 5% to 10% of GBS cases in 
Western countries and it is more common in Eastern Asia, accounting for up to 25% of 
Japanese cases. MFS usually have a good clinical outcome but some develop limb weakness 
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and respiratory insufficiency (termed MFS–GBS overlap syndrome). Other local variants of 
GBS, such as the pharyngeal–cervical–brachial (PCB) variant have also been reported. PCB 
manifests with ptosis, facial, pharyngeal and neck flexor weakness that spreads to upper limbs 
and spares the legs relative to the arms.(18) The subtypes vary globally and are dependent 
on trigger/antecedent risk factors. (6) 
1.4 HIV and GBS: 
Several reviews suggest that GBS tends to occur early in HIV with high CD4 counts (>500). (19) 
Brannagan et al described ten patients, and amongst these ten, GBS was frequently found to 
be the first manifestation of HIV infection, even without decline of CD4 counts, at the time of 
seroconversion. However, 40% of their  patients developed GBS after onset of AIDS and the 
CD4 count was less than 200.(19) In a Zimbabwean  study of 32 GBS patients, 55% were HIV 
infected, which may relate more to the background prevalence of HIV infection than to a 
specific association with GBS.CD4 counts were not recorded in that study.(11)  Whilst GBS has 
been reported in patients with very severe immunosuppression (CD4 <50 per μL cells), an 
acute demyelinating polyradiculoneuropathy (AIDP) in the context of profound 
immunosuppression may be caused by direct cytomegalovirus infection, and this should 
therefore be sought and treated appropriately.(20) Diffuse infiltrative lymphocytosis 
syndrome (DILS) most often manifests as an acute or subacute painful sensorimotor 
polyneuropathy and may be an AIDP mimic. Sicca symptoms and CD8 hyperlymphocytosis are 
common non-specific features in DILS, but because nerve biopsy is required for a definitive 
diagnosis it may occasionally be difficult to separate HIV-associated GBS from severe DILS 
neuropathies.(19) Evidence of CD8  infiltration is routinely sought after at our centre. 
 A few case reports have presented GBS as an immune reconstitution syndrome (IRIS) 
phenomenon. IRIS may develop as the ‘unmasking’ or  paradoxical worsening of pre-existing 
infection in the context of immune recovery.(21) Rapid recovery of T-cell immunity in 
response to pre-existing antigens occurs resulting in disease manifestation or a clinical 
deterioration. One of the case reports was that of a male with CD4 cell count of 545 cells/L 
who presented with symptoms of rapidly progressing weakness, bilateral lower limb 
paraesthesia, and partial inability to ambulate, two months after antiretroviral initiation.(20) 
The other report was of a male patient with a CD4 count of 31 cells/ μL who presented with 
neurological fallout 26 days after antiretroviral initiation.(21) The proposed underlying 
mechanism of IRIS depends on the degree of immune restoration following antiretroviral 
initiation, pre-existing antigen burden and host genetic vulnerability.(20) Cerebrospinal fluid 
(CSF) in HIV associated-AIDP may be atypical with a higher cellular response in the CSF: up to 
50 cells per μL is still considered acceptable for diagnosis in the context of HIV. 
Electrophysiology is similar in both HIV and HIV uninfected cases. Treatment remains the 
same despite HIV infection, and includes intravenous immunoglobulin and plasmapheresis. 
(19) 
1.5 Course, complications and outcomes: 
GBS is well recognized for its acute onset and heterogeneity in course and outcomes. It is 
associated with a favourable outcome in 80% of cases. However, mortality rates vary from 
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3% to 7% in regions like  North America and Europe to 15% in Bangladesh.(6) In a large 
American  based cohort study of 4954 participants recruited over 5 years,  Alsheklee et al 
found that  88% of their patients presented with milder disease  with minimal or no 
neurological deficits upon discharge and the  in-hospital mortality rate was 2.58%.(22) 
According to Islam et al, outcome is worse in low income countries like Bangladesh, where 
85% of patients receive no treatment, 15% die and 30% remain severely disabled.(8) 
Respiratory failure, cardiac arrhythmias and deep vein thrombosis are well recognized 
complications of GBS  which may prove fatal.(6) Van den Berg et al reported on clinical 
outcomes in GBS after prolonged mechanical ventilation, noting that 58% of patients were 
able to walk unaided at six month follow up. Despite this positive outcome, almost all 
ventilated patients reported residual deficits (functional impairment in lower limbs 80%, 48% 
hands, 36% sensory deficits, 20% fatigue and pain) after follow up of two years.(23) The 
characteristics consistently related to poor prognostic outcome in Guillain-Barré syndrome 
are high age (aged 40 years and over), preceding diarrhoea (or C jejuni infection in the past 4 
weeks), and high disability at nadir.(6) In 2005 a study reviewed how patients perceived their 
physical and social situation one year after GBS. Of the 90 patients evaluated from the Dutch 
division of an international, multicentre, double-blind, placebo-controlled trial comparing 
treatment with intravenous immunoglobulin (IVIg), 33% felt completely cured after one year.  
In this study, on assessment after one year, sensory disturbances of arms were moderately 
or severely reported in 22.2% of cases and 36.6% in legs. At one year evaluation, loss of power 
was reported in arms ( 30%) and legs (48,9%). (24) 
1.6 Treatment: 
Several randomised controlled trials (RCT) have shown that IVIg and plasma exchange are 
effective immunotherapies. Although these studies were conducted in high income countries 
where the most common variant is AIDP.(6)Plasma exchange has been shown to be beneficial 
when initiated within first four weeks, however it is most effective when started early.(25) 
The first RCT  on the use of IVIg (0.4g IVIg/kg/day for five days) was published in 1992, proving 
that IVIg is as effective as plasma exchange.(25) Oral steroids (or intravenous 
methylprednisolone 500 mg/day for five consecutive days) alone are not beneficial in GBS. 
(26) It is recommended that treatment is started as soon as possible in particular in patients
who walk needing assistance, are bed bound or ventilated.(26) Ambulant cases of mild GBS
may experience prolonged functional impairment however treatment is only recommended
in those who develop additional features like autonomic disturbance, facial or bulbar
weakness. (25) Miller Fisher syndrome may require supportive care only because of a
relatively benign course.(26)/(25) Clinical severity of acute Bickerstaff’s brainstem
encephalitis and overlap with GBS suggests treatment with IVIg or plasma exchange is
reasonable. (25)
2. Aims:
The primary aim of this study is to describe the clinical presentation and outcomes of patients 
with a diagnosis of acute GBS  who were admitted to Groote Schuur Hospital (GSH), Cape 
Town, and enrolled in IGOS.  
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The secondary aim is to describe and compare GBS participants with and without HIV 
infection. 
3. Methods:
This prospective observational outcome cohort  was conducted by the Division of Neurology, 
Department of Medicine, Groote Schuur hospital, University of Cape Town between 1 June 
2014 and  31 January 2017.  
Groote Schuur hospital is a specialist tertiary, public health care sector hospital located in 
Cape Town, South Africa. It is a referring hospital for secondary hospital and clinics in Cape 
Town city centre and its surrounding areas, serving largely lower to middle socio-economic 
population who do not have medical insurance. 
IGOS is a prospective multicentre, international observational outcome study collecting 
standardised clinical, electrophysiological and laboratory data and biosamples on participants 
presenting with acute GBS worldwide. The study has its coordinating centre in the 
Netherlands at Erasmus University and is being conducted in collaboration with the Peripheral 
Nerve Society and Inflammatory Neuropathy Consortium (INC). IGOS commenced enrolment 
in May 2012 and current enrolment is 1751 participants. Their main aim is to explore the 
pathogenesis  of GBS and the individual clinical course, prognosis, treatment response and 
outcome.(27) The Neurology Division at Groote Schuur Hospital, University of Cape Town, is 
a participating centre in the IGOS initiative, under local investigator, Dr Kathleen Bateman, 
and recruited participants with acute GBS from 1 June 2014 to 31 January 2017. 
While IGOS seeks to better understand GBS on a global level, this cohort aims to understand 
GBS in this local setting in South Africa and the effect, if any, of HIV on GBS. 
3.1 Study population: 
Patients who fulfil the diagnostic and inclusion criteria of the IGOS study, are eligible for 
enrolment, provided that informed consent is obtained. 
3.2 Inclusion criteria: 
All participants fulfilled the diagnostic criteria for GBS from the National Institute of 
Neurological Disorders and Stroke (NINDS; Appendix A). All patients with Miller Fisher 
syndrome (MFS) and other variants of GBS, including overlap syndromes were  included. 
Participants included  were age 18 yrs and older and presented to Groote Schuur hospital, 
Cape Town, South Africa within two weeks after onset of weakness. All participants who  were 
willing and able to be followed  up for at least one year were enrolled. Informed consent was 
obtained for the International Guillain-Barré Syndrome Outcome Study (IGOS) in all 
participants. 
There were no exclusion criteria so as to limit selection bias, however participants who were 
misdiagnosed were excluded from further follow-up visits and relevant analyses. 
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3.3 Study data collection, procedures, outcome measures: 
Clinical data for each participant was recorded per IGOS protocol at four visits (entry, week 4, 
week 26 and week 52) using specific data entry forms for each visit. The clinical data sheets 
capture demographics, comorbidity and antecedent events. In addition, the first clinical 
symptoms and signs of GBS, the timing and key features of the diagnosis, neurological 
examination findings and the clinical course were recorded. The extent of clinical 
manifestations of GBS were documented in detail, including cranial nerve deficits, limb 
weakness, sensory deficits, ataxia, limb tendon reflexes, GBS disability scale (Hughes et al., 
1978) (Appendix C), pain, autonomic dysfunction, respiratory failure, and associated medical 
complications.(27)  
Questionnaires and clinical examination for the first visit (entry) focus on potential clinical 
predictors of outcome, including co-morbidities and antecedent infections (upper respiratory 
tract infection, cold, gastroenteritis, urinary tract infection, vaccination, surgery). The 
presence of pain is noted and characterised, MRC sum score, reflexes, ataxia, autonomic 
dysfunction, cerebrospinal fluid (CSF) protein and leukocytes were captured. GBS disability 
score was recorded at each follow up. 
Questionnaires and clinical examination for weeks 4, 26 and 52 focus on the above as well 
as the presence of complications (pneumonia, sepsis, deep vein thrombosis, pulmonary 
embolism, pressure ulcer) and GBS disability scores. Transition to chronic inflammatory 
demyelinating polyneuropathy (CIDP) is also recorded.  
Voluntary HIV testing is offered routinely to all patients attending the Neurology Division at 
Groote Schuur Hospital presenting with a suspected inflammatory neuropathy, and patients 
undergoing testing are provided suitable pre- and post-test counselling. 
Electrophysiology tests were performed within the first or second week of admission. The 
tests were classified according to the Hadden criteria (Appendix D). 
3.4  Data analysis: 
All clinical data was collated and analysed. Clinical factors such as clinical variants, age of 
onset, CSF parameters, GBS disability score at follow up, treatment options, antecedent 
triggers, seasonal variation, number of participants requiring ICU admission and ventilation 
and number of HIV infected vs non-infected participants are tabulated below. 
Data was entered into an excel database for analysis using STATA version 14.1 (Texas, USA). 
Categorical variables were expressed as proportions while numerical variables were 
described using mean (standard deviations) or medians (interquartile ranges) depending on 
the normality of the data. The Chi square test was used to compare proportions, medians and 
means. A Chi square test for trend was used to compare GDS scores over time between HIV-
infected and -uninfected participants. A  p-value of <0.05 was considered to be significant. 
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4. Ethical approval:
The original study was approved in 2014 (HREC REF: (267/2014)). The permission to do this 
research as a sub-study towards an MMed degree was approved by the Human Research 
Ethics Committee of the Faculty of Health Sciences at the University of Cape Town (HREC 
REF:852/2017). Please see Appendix B. 
5. Results:
5.1 Demographic, clinical features and laboratory investigations: 
31 participants were recruited within the time period 1 June 2014 and 31 January 2017. One 
death was recorded at week one in intensive care unit (ICU). One patient’s diagnosis was 
amended to  acute onset chronic inflammatory demyelinating polyradiculoneuropathy 
(CIDP). During her admission, on repeated history-taking, this patient described a prior 
episode of ‘acute GBS’ requiring hospitalization at a secondary hospital as well as multiple 
self-limited relapses since her first episode of polyneuropathy. She responded to treatment 
with steroids and immunosuppressants, but suffered a further relapse in the course of the 
next year. Her diagnosis was revised therefore to CIDP and she was excluded from further 
IGOS follow-up. 29 participants therefore had further follow-up data obtained. One year 
follow up was conducted in 83 % of participants and 79% had a six month follow up. 
63% participants were male and the median age was 39 years. 57%  participants were of 
mixed African ancestry, and 37%  were black African. Reported antecedent infections were 
found in 73% of cases, upper respiratory tract infections (URTIs) in 46%  and acute 
gastroenteritis (AGE) in 27%. Co-morbid HIV infection was found in 30%, tuberculosis 15%  
and neurosyphilis in 3% of cases.  Co-morbid medical diseases found in 18 % patients, of which 
6% participants suffered from Diabetes mellitus.  
If a history of antecedent infection was present, median days from infection to symptom 
onset was 10.5 days (IQR 7-17.5). Nadir was reached by 72% at enrolment  which by defined 
inclusion criteria needed to occur within two weeks of symptom onset. GBS occurred in 
winter in 47% of cases.  AIDP (67%) and AMAN (17%) were the most common phenotypes.  
Miller Fisher or Miller Fisher overlap was found in 13% of cases with one case a PCB variant. 
The mean CSF protein was 0.88 g/dL (standard deviation (SD) = 0.58) and the mean CSF 
leucocyte was 5.58 cells/𝜇𝐿 (SD = 12.63). 
See Table 1 for demographic, clinical and laboratory features: 
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Demographics, n (%) All (n=30) HIV + (n=9) HIV – (n=21) p-value
*
Male sex 19 (63) 4 (44) 15(71) 0.25 
Age in years, mean ( SD) 39 (14.2) 40 (8) 39 (16) 0.86 
Ethnicity 
African 11 (37) 8 (89) 3 (14) <0.001 
European ancestry 1 (3) 0 1 (5) - 
Mixed African ancestry 18 (60) 1 (11) 17 (81) - 
Co-morbid infections 
HIV 9 (30) - - - 
TB 5 (17) - - - 
Syphilis 1 (3) - - - 
None 19 (63) - - - 
Antecedent infection 
URTI 14 (46) 4 (45) 10 (48) 0.96 
AGE 8 (27) 3 (33) 5 (23) 0.54 
None 8 (27) 2 (22) 6 (29) - 
GBS variants 
AIDP 20 (67) 6 (67) 14 (67) 0.22 
AMAN 5 (17) 0 5 (24) - 
MFS or MFS overlap 4 (13) 2 (22) 2 (9) - 
PCB 1 (3) 1 (11) 0 - 
Lab investigations : 
Serology 
CD4, cells/L, mean (SD) 304 (242) 
CSF 
CSF Protein g/dL, median (IQR) 0.65 (0.42 – 1.33) 1.40 (0.70 – 1.90) 0.60 (0.40 – 0.90) 0.05 
CSF Leucocytes cells/ L, 
median (IQR) 
5.58 (0-5.50) 2.00 (1.00-7.00) 1.00(0-4.00) 0.26 
Table 1:  Baseline characteristics 
* Chi square test used to calculate p-value
TB – Tuberculosis, URTI  - upper respiratory tract infection, AGE – acute gastroenteritis AIDP
– acute inflammatory demyelinating polyneuropathy, AMAN – acute motor axonal
neuropathy, MFS – Miller Fisher syndrome, PCB – pharyngeal-cervical-brachial variant
5.2 Treatment, complications and outcomes: 
IVIG was administered in 47% participants with no adverse effects. 30% required IVIG with 
neuropathic analgesics and  4 participants (13 %) did not receive any treatment.  
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Pain was present in 52% of participants on entry, and a greater proportion of participants 
reported pain at entry than at any other visit. Nevertheless, 79% of participants reported pain 
at some point in their course. The most common types of pain reported were muscle pain 
(27%) and distal paraesthesia (27%).  
Overall, GBS-related complications occurred in 46% of participants. The major complication 
was  pneumonia which occurred in  23% of the total group, and all required 
intubation/ventilation with 30% requiring ICU care. Other septic complications (drip site or 
systemic) were less common, 6% of the entire group. No complications were found in 54% of 
participants.  
At entry 83% had GDSs >4 indicating severe disability. Ability to walk unaided (or GDS ≥3) was 
regained by 38% at 4 weeks, 76% at 6 months and 79% at 1 year (see figure 1). Three 
participants remained severely affected at 1 year (GDSs of >3). One participant died during 
the cohort. The cause of the one death was considered unrelated to her GBS admission: she 
developed massive spontaneous intrahepatic haemorrhage secondary to a presumed 
adenoma. Repeated attempts at hepatic artery embolization were unsuccessful and she 
developed multiorgan failure and demised. 
See Table 2 for treatment, complications and outcomes: 
Treatment, n (%) All (n=30) HIV+ (n=9) HIV – (n=21) p-value*
IVIG 14 (47) 4 (45) 10 (48) 0.87 
IVIG  + Neuropathic analgesics 9 (30) 3 (33) 6 (29) 0.79 
Neuropathic analgesics 3 (10) 2 (22) 1 (5) 0.14 
PE 0 - - - 
None 4 (13) - - - 
Complications 
None 19 (63) - - - 
Pneumonia 8 (27) - - - 
Sepsis 2 (7) - - - 
Other 6 (20) 
Outcomes 
Intubation 7 (23) 3 (33) 4 (19) 0.64 
ICU 9 (30) 4 (44) 5 (24) 0.39 
Death 1 (3) 0 1(5) 0.51 
Table 2:  Treatment, complications and outcomes of participants 
* Chi square test used to calculate p-value
IVIG – intravenous immunoglobulin, PE – plasma exchange, ICU – intensive care unit
sepsis – drip site and/or systemic
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Figure 1: GBS disability scores at follow up: 0  - A healthy state.   1 - Minor symptoms and capable of 
running.    2 - Able to walk 10 metres or more without assistance but unable to run.   3 - Able to walk 10 metres 
across an open space with help.  4 -Bedridden or chair bound.  5 -Requiring assisted ventilation for at least part 
of the day.   6 -Dead 
5.3 GBS and HIV infection: 
See table 1 for comparison between HIV-infected and uninfected participants. 
Nine HIV-associated GBS participants were recorded. Proportionally in this cohort more 
females than males (45.5% vs 21%) were HIV-infected. Age was similarly reflected in the two 
groups, the overall mean age was 39 years. More black African participants were noted in the 
HIV-infected (89%) than in the -uninfected group, with statistical significance (p–value < 
0.001). The HIV-infected and -uninfected groups had similar rates of antecedent infections; 
upper respiratory infection (URTI) (45% and 48% respectively), whilst acute gastroenteritis 
(AGE) occurred in 33% HIV- infected patients and 23% in HIV-uninfected patients. AIDP was 
the most common GBS variant in both groups. However more HIV-infected participants had 
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Miller Fisher syndrome (MFS) or MFS overlap (22%) than HIV-uninfected (9%) and the only 
pharyngeal-cervical-brachial variant (PCB) was HIV-infected. Unfortunately our numbers are 
too small to reach any statistical significance. 
Of  note, no AMAN variants were recorded in the HIV-infected group.  
In the HIV-infected group, the mean CD4 was CD4  304 cells/L (SD = 242). A  statistical trend 
was noted  towards higher CSF protein in HIV infection (p-value 0.05). More HIV-infected 
participants (88%) were unable to walk at entry compared to HIV-uninfected group (68%). 
However this did not reach statistical significance. At 52 weeks the inability to walk was similar 
in HIV-infected (11%) and uninfected (9%) groups; see Figure 2. HIV-infected GBS cases 
received similar treatment modalities as uninfected GBS patients namely; IVIG alone in 45% 
of cases, IVIG with neuropathic agents in 33% and 22% received neuropathic agents alone. 
Intubation (33%) and ICU admission (44%) were similarly needed  in HIV-infected participants. 
No deaths were recorded in the HIV-infected GBS patients. 
Figure 2: Inability to walk unaided (GDSs ≥ 3) and HIV status during follow-up: 
Chi square for trend p-value 0.68.   No – number GDS – GBS disability score 
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6. Discussion:
This study highlights the clinical presentation and outcomes of GBS in a low to middle income 
country (LMIC) like South Africa. Of the 29 participants that were finally evaluated, good 
follow up was achieved with a one year follow up in 83 % of participants and 79% at six month 
follow up. The main findings were that AIDP was the most common phenotype in our cohort. 
Comorbid infections like HIV and TB co-occurred frequently. The HIV-associated GBS 
participants’ had a mean CD4 304 (SD = 242) cells/L. A favourable outcome, namely being 
able to walk unaided or having no/minor symptoms by six months, was obtained in 76% of 
participants. Mortality was low with one death reported in this cohort. Although, the cause 
of death (massive spontaneous intrahepatic haemorrhage secondary to a presumed 
adenoma) was entirely unrelated to GBS as  already described.  
In this cohort, 73% reported antecedent infections with the majority being URTI (46%). A high 
rate of co-morbid HIV infection was noted (30%) and tuberculosis (15%). This differs from 
other LMIC like Bangladesh where 46% of their participants reported antecedent infection, 
predominantly diarrhoea with only a few cases reporting respiratory infection. GBS in 
Bangladesh is frequently preceded by an enteric infection, Campylobacter jejuni.(28) The 
antecedent infection rate in this cohort was similarly reflected in systematic literature reviews 
such as McGrogan et al.(17) in which 40–70% of cases recorded an infection before onset 
with 22–53% having an upper respiratory tract infection and 6–26% a gastrointestinal 
infection.(17) Unlike this study  where the mean age is 39 years, a number of studies have 
commented on a bimodal pattern of incidence by age, with peaks occurring in young adults 
and the elderly.(17) 
It is notable that AIDP (67%) was the most common phenotype in our study with AMAN 
present in far fewer participants (17%). This is in keeping with literature from North America 
and Europe where demyelinating GBS is present in 60-80% of North-American and European 
patients.(7) Axonal GBS has been reported in 3-17% in Europe, in 23-65% in Asia(15)  and in 
67% in Bangladesh.(8) In a Bangladesh cohort  where AMSAN (58%) was the predominant 
type; AMAN, AIDP and MLF constituted 28%, 10% and 4 % of their study group 
respectively.(28) This difference in presentation compared to Bangladesh may relate to the 
difference in antecedent infection with C. jejuni, which is known to be associated with axonal 
GBS. The frequency of MFS varies widely in different regions from 3% in Europe to 34% in 
Eastern Asia.(29) MFS was also  present in the minority of cases (13%) in our cohort, but was 
more frequently seen than in Europe. 
Co-morbid infections like HIV and TB were found in 44% of our participants. South Africa has 
the largest HIV epidemic. According to Statistics SA (www.statssa.gov.za) July 2018, the 
estimated overall HIV prevalence rate is approximately 13,1% among the South African 
population. The total number of people living with HIV is estimated at approximately 7,52 
million in 2018. In 2017 HIV prevalence in Western Cape was at 12.6%. For adults aged 15–49 
years, an estimated 19% of the population is HIV-positive. The reason for a high rate of HIV 
co-infection in our cohort may be a chance finding reflective of a high prevalence of these 
infections in the general population. However, it may be that these infections are implicated 
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in GBS pathogenesis. A previous study from this region by Henning et al. estimated  more 
than 18 times higher incidence of GBS in HIV-infected people than in those -uninfected with 
HIV.(30) Accurate epidemiological data to answer this observation is not available for South 
Africa.  
We saw no significant differences between HIV-infected and HIV-uninfected participants in 
terms of antecedent infections. The HIV positive group had no AMAN cases and more MFS, 
but this did not reach clinical significance. A  non-significant difference was a higher CSF 
protein in HIV-infected patients (p=0.05). This is not unexpected as HIV-infected patients may 
have a raised CSF protein, owing to  HIV infection.(19) In HIV, GBS is thought to occur more 
frequently in the context of a preserved rather than a depleted CD4  count, and this was 
evident in our cohort where the mean CD4  count 304 (SD = 242) cells/L was relatively 
preserved. (19)The inability to walk was noted in 88% HIV-infected participants compared to 
68% HIV-uninfected participants at entry, However, this did not reach statistical significance. 
At one year the inability to walk was similar in HIV-infected (11%) and uninfected (9%) groups, 
and the rate of recovery did not differ between groups. This observation is consistent with 
previous reports noting that HIV-infected GBS patients respond to treatment and recover 
spontaneously in a similar fashion to HIV-uninfected GBS patients.(19) Treatment therefore 
does not differ on the basis of HIV serostatus, and includes use of plasmapheresis and 
intravenous immunoglobulin. (19) In 2003, Schleicher et al. performed a retrospective review 
of 13 patients admitted to two tertiary academic hospitals in Johannesburg, South Africa 
(seven were HIV negative and six were HIV positive). Their aim was to determine the effect of 
HIV on ICU outcome in patients with GBS. The HIV-seropositive and seronegative had similar 
clinical presentations and severity of disease. The HIV-positive tended to be younger (34.5 vs 
47 years of age) and included more men than in the HIV-negative group. However, these 
differences were not statistically significant. The mean CD4   322.5 cells/L is similar to our 
cohort. The study  revealed a similar ICU outcome between HIV-infected and uninfected 
groups especially if  CD4 count is greater than 200 cells/L. A low CD4 count was thought to be 
associated with a poor outcome as the one death reported  in this study was an  HIV-infected 
participant with a CD4 46 cells/L, who died from severe sepsis.(31) 
TB was the second most common co-morbid infection in this study. In addition to the HIV 
pandemic, South Africa also has the highest tuberculosis incidence globally 
(781/100,000).(32)  TBFacts.org state that the highest TB Incidence rates in South Africa occur 
in the provinces  Eastern Cape, KwaZulu-Natal and the Western Cape with 692, 685 and 681 
per 100,000 respectively for 2015. The burden of TB differs with age and peaks in TB 
notification rates in the HIV-uninfected population occurs at ages 0−5, 20−24, and 45−49 
years. In the HIV-infected population, however, there is little disparity in age.(33)  As a result 
of the high incidence of TB in the Western Cape, it is not unexpected to find a high rate of TB 
comorbidity in our GBS cohort (15% of  participants). In a local study from Tygerberg hospital, 
Cape Town, South Africa; Henning et al.  sought to determine the validity of an association 
between Neuromyelitis optica (NMO) and active pulmonary tuberculosis (TB).(34) The control 
group comprised of hospitalized GBS patients. Two of the 14 controls (14%) were diagnosed 
with TB during hospitalisation, one had active PTB and the other had TB adenitis without 
pulmonary involvement. All participants were screened for HIV, six patients were 
seropositive. The prevalence of HIV infectivity was not significantly different between the 
cases and controls (p=0.089). (34) The incidence of TB in GBS reported in their study, also 
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performed in the Western Cape, is similar to that in our cohort. A few case studies in Asia 
have also described comorbid TB and GBS, namely two  reported cases in Sri Lanka(35) and 
one case in Singapore.(36) It is unclear how TB may affect GBS disease. The co-occurrence of 
TB with GBS could be incidental in these endemic areas. However, GBS might be an 
autoimmune reaction to tuberculous bacilli or GBS may be misdiagnosed in cases of direct 
tuberculous nerve root involvement. Microbiological confirmation of tubercle bacilli in GBS 
can be challenging. This may be  due to GBS associated respiratory muscle weakness leading 
to difficulty obtaining sputum for culture and may be due to a low diagnostic sensitivity of 
cerebrospinal fluid.(36) 
In this study, recovery in the ability to walk was used as a surrogate for a favourable outcome 
and it was obtained using the validated GBS disability scoring system. At entry, 83% had GDSs 
>4 indicating severe disability. The ability to walk unaided was regained by 38% at 4 weeks,
76% at 6 months and 79% at 1 year. Three participants remained severely affected at 1 year
(GDSs of >3). Our cohort showed similar, if slightly worse, outcomes to a cohort of 397
patients  reported by Walgaard et al in 2011 (37) in which 50% had a poor outcome at 4 weeks
30% at 3 months, and 19% at 6 months after hospital admission.(37)
It is well recognized that complications may occur in GBS. In this cohort, GBS-related 
complications occurred in 46% of participants with pneumonia and intubation/ventilation 
(23%) being the most common. A similar rate of intubation and ventilation requirements 
were recorded in this cohort as compared to literature where  20–30% of patients develop 
respiratory failure and need ventilation at an intensive care unit (ICU).(6) The 3% mortality 
rate found in this cohort is not reflective of other works as the cause of the  one death is 
clearly unrelated to GBS and its complications. Van den Berg et al in 2013 described mortality 
in Guillain-Barré syndrome and they found a relatively low mortality rate of 2.8% in the first 
6 months and 3.9% in the first year.(29) It was found to be influenced by the high number of 
patients receiving IVIG or plasma exchange (96%) and the high number of patients not 
requiring support in ICUs (72%). Risk factors for death were older age, severity of weakness 
at entry mechanical ventilation, delay from onset of weakness to entry. In the acute phase, 
patients died of cardiovascular and autonomic complications. However, during the recovery 
phase, after neurologic improvement, two- thirds of the GBS patients, died from pulmonary 
infections or cardiovascular complications.(29) 
In this cohort, patients with acute GBS, were offered treatments consistent with international 
guidelines.(38) IVIG alone was administered in 47% and IVIG with agents for neuropathic pain 
in 30% of participants. Four out of 29 participants did not require treatment. Pain 
management in our cohort appears inadequate: a high proportion (79%) of participants 
reported pain at some point in their course but only 29% were recorded as receiving 
neuropathic pain therapy with their IVIG. The reasons for this mismatch are not clear,  but 
may relate to the timing of when participants treatment records were evaluated for study 
purposes. Nevertheless, this observation underscores the fact that pain occurs frequently in 
GBS and treatment of pain should not be overlooked. 
Here we have described the clinical manifestations, treatment and outcome of GBS in our 
local setting of Cape Town South Africa. This study has again highlighted a high rate of co-
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morbid HIV and TB. It would be of scientific interest and potential clinical relevance in areas 
of high prevalence to elucidate the role of these infections in GBS. However, from this small 
cohort, there appears to be no significant difference in GBS in HIV-infected versus -uninfected 
people. This study confirms that it remains appropriate to use current treatment regimens 
for GBS irrespective of HIV status in our local context.   
7. Limitations
This study has a limited number of participants and the selection bias is another factor to 
note. The participants were recruited from a single academic hospital rather than a 
population or primary health base, and so may not truly reflect the population of Western 
Cape.  
IGOS stipulated a two week inclusion criteria. This may have excluded slower onset cases who 
achieve nadir in less than four weeks as per diagnostic criteria. 
8. Conflict of interest
The author affirm that this study and its interpretations were not under any financial or 
otherwise competing interest. 
9. Conclusion:
In this cohort, infections like HIV and TB frequently co-occurred in GBS.  It is unclear if this is 
due  to a valid disease association or rather a reflection of  the high background prevalence 
of HIV and TB in the Western Cape. AIDP was the most common phenotype unlike other LMIC 
regions such as Asia where AMAN predominates. We observed similar presentation and 
outcomes of GBS in HIV-infected versus HIV-uninfected participants and our mortality rate 
was low. 
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Appendix A: 
Asbury and Cornblath Diagnostic criteria: 
Required features 
▪ Progressive weakness in both arms and legs
▪ Areflexia (or hyporeflexia).
Features supportive of diagnosis 
▪ Progression of symptoms over days to 4 weeks
▪ Relative symmetry
▪ Mild sensory signs or symptoms
▪ Cranial nerve involvement, especially bilateral facial weakness
▪ Recovery beginning 2 to 4 weeks after progression ceases
▪ Autonomic dysfunction
▪ Absence of fever at onset
▪ Typical CSF (albuminocytologic dissociation)
▪ EMG/nerve conduction studies (characteristic signs of a demyelinating process in the
peripheral nerves)
Features casting doubt on the diagnosis 
▪ Asymmetrical weakness
▪ Persistent bladder and bowel dysfunction
▪ Bladder or bowel dysfunction at onset
▪ >50 mononuclear leukocytes/uL or presence of polymorphonuclear leukocytes in CSF
▪ Distinct sensory level.
Features that rule out the diagnosis 
▪ Hexacarbon abuse
▪ Abnormal porphyrin metabolism
▪ Recent diphtheria infection
▪ Lead intoxication
▪ Other similar conditions: poliomyelitis, botulism, hysterical paralysis, toxic
neuropathy.
Reference:  
Adapted from Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain‐
Barré syndrome. Ann Neurol 1990;27 Suppl:S21‐4 
NINDS: 
NINDS Diagnostic criteria for Guillian Barré Syndrome: 
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Features required for diagnosis 
● Progressive weakness in both arms and legs (might start with weakness only in the
legs)
● Areflexia (or decreased tendon reflexes)
Features that strongly support diagnosis 
● Progression of symptoms over days to 4 weeks
● Relative symmetry of symptoms
● Mild sensory symptoms or signs
● Cranial nerve involvement, especially bilateral weakness of facial muscles
● Autonomic dysfunction
● Pain (often present)
● High concentration of protein in CSF
● Typical electrodiagnostic features
Features that should raise doubt about the diagnosis 
● Severe pulmonary dysfunction with limited limb weakness at onset
● Severe sensory signs with limited weakness at onset
● Bladder or bowel dysfunction at onset
● Fever at onset
● Sharp sensory level
● Slow progression with limited weakness without respiratory involvement (consider
subacute
● inflammatory demyelinating polyneuropathy or CIDP)
● Marked persistent asymmetry of weakness
● Persistent bladder or bowel dysfunction
● Increased number of mononuclear cells in CSF (>50×10E6/L)
● Polymorphonuclear cells in CSF
Reference: 
Adapted from Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain‐
Barré syndrome. Ann Neurol 1990;27 Suppl:S21‐4 
Diagnostic criteria for Miller Fisher Syndrome (MFS) 
Features required for diagnosis 
● Bilateral ophthalmoparesis or ophthalmoplegia
● Ataxia
● Areflexia (or decreased tendon reflexes)
● Features that support diagnosis
● Progression of symptoms over days to 4 weeks
● Relative symmetry of symptoms
● Mild limb weakness (in case of prominent limb weakness, consider GBS‐MFS overlap
syndrome)
● Mild sensory symptoms or signs (in case of prominent sensory symptoms or signs,
consider GBS‐MFS overlap syndrome)
27 
● Facial palsy and/or bulbar palsy
● Presence of serum IgG antibodies against ganglioside GQ1b
● Nerve conduction studies: no changes in extremities
● High concentration of protein in CSF, cytoalbuminologic dissociation
Features that should raise doubt about the diagnosis 
● Alterations in consciousness
● Corticospinal tract signs
● Fever at onset
● Marked persistent asymmetry of weakness
Reference: 
Adapted from Sejvar JJ, Kohl KS. Guillain‐Barré syndrome and Fisher syndrome: Case 
definitions and guidelines for collection, analysis, and presentation of immunization safety 
data. Vaccine 2011;29:599‐612 and van der Meché FGA, van Doorn PA. Diagnostic and 
Classification Criteria for the Guillain‐Barré Syndrome. Eur Neurol 2001;45:133‐139. 
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Appendix C: GBS disability score 
 
The GBS disability score has 7 scores for disability, ranging from a healthy state to dead:  
1. 0  A healthy state  
2. 1  Minor symptoms and capable of running  
3. 2  Able to walk 10 metres or more without assistance but unable to run  
4. 3  Able to walk 10 metres across an open space with help  
5. 4  Bedridden or chair bound  
6. 5  Requiring assisted ventilation for at least part of the day  
7. 6  Dead  
Reference  
Adapted from Hughes RA, Newsom‐Davis JM, Perkin GD, Pierce JM. Controlled trial 
prednisolone in acute polyneuropathy. Lancet 1978;2:750‐3.  
 
Appendix D: 
Hadden criteria: 
1. Normal 
(All the following in all nerves tested) DML 5100% ULN 
F wave present with latency 5 100% ULN MCV 2100% LLN 
dCMAP 2100% LLN 
pCMAP 2100% LLN 
pCMAP/dCMAP ratio >0.5  
2. Primary demyelinating 
(At least one of the following in each of at least two nerves, or at least two of the following 
in one nerve if all others inexcitable and dCMAP 210% LLN) MCV <90% LLN (85% if dCMAP 
<50% LLN) DML >110% ULN (120% if dCMAP <loo% LLN) pCMAP/dCMAP ratio <0.5 and 
dCMAP 2 2 0 % LLN F-response latency >120% ULN  
3. Primary axonal 
None of the above features of demyelination in any nerve (except one demyelinating 
feature allowed in one nerve if dCMAP <lo% LLN), and dCMAP <80% LLN in at least two 
nerves  
4. Inexcitable dCMAP absent in all nerves (or present in only one nerve with dCMAP <lo% 
LLN)  
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5. Equivocal 
Does not exactly fit criteria for any other group  
"Modified from Ho and colleague. 
DML = distal motor latency; ULN = upper limit of normal; MCV = motor conduction velocity; 
LLN = lower limit of normal; dCMAP = compound muscle action potential amplitude after 
distal stimulation; pCMAP = compound muscle action potential amplitude after proximal 
stimulation.  
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